Acadian Asset Management’s PharmaCyte Biotech PMCB Stock Holding History

Acadian Asset Management’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,851	Closed	-$5K	–	2044
2024 Q3	$5K	Hold	2,851	–	–	﹤0.01%	2037
2024 Q2	$5K	Sell	2,851 -738	-21%	-$1.59K	﹤0.01%	1716
2024 Q1	$8K	Sell	3,589 -1,200	-25%	-$2.6K	﹤0.01%	1522
2023 Q4	$10K	Sell	4,789 -2,337	-33%	-$5.07K	﹤0.01%	1623
2023 Q3	$14K	Hold	7,126	–	–	﹤0.01%	1580
2023 Q2	$20K	Sell	7,126 -2,138	-23%	-$6.42K	﹤0.01%	1645
2023 Q1	$26K	Buy	+9,264	New	+$27.2K	﹤0.01%	1622

Other funds holding PMCB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management's PMCB Position: Q4 2024 in Review

Acadian Asset Management sold out of PharmaCyte Biotech (PMCB) in Q4 2024, closing a stake of 2,851 shares — an estimated $5K sold.

Acadian Asset Management first reported a position in PMCB in Q1 2023 and held it in 7 quarters. The position peaked at $26K in Q1 2023. 21 funds tracked by Wall St. Rank hold PMCB as of Q4 2024.

Acadian Asset Management reported no remaining PharmaCyte Biotech position as of Q4 2024 after selling out during the quarter.
Acadian Asset Management sold 2,851 PharmaCyte Biotech shares in Q4 2024, an estimated $5K.
Acadian Asset Management first reported a position in PharmaCyte Biotech in Q1 2023 and held it in 7 quarters.
Acadian Asset Management's PharmaCyte Biotech position peaked at $26K in Q1 2023.
21 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.